Antiviral activity and dose optimum of recombinant macrophage colony- stimulating factor on herpes simplex genitalis in guinea pigs
The antiviral activity of recombinant human macrophage CSF (M-CSF) against genital herpes simplex virus type-2 (HSV-2) infection in guinea pigs was investigated. M-CSF stimulates proliferation of human and guinea pig peripheral blood monocytes, specifically the plastic adherent esterase-positive mon...
Gespeichert in:
| Veröffentlicht in: | The Journal of immunology (1950) 1991-05, Vol.146 (10), p.3578-3582 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3582 |
|---|---|
| container_issue | 10 |
| container_start_page | 3578 |
| container_title | The Journal of immunology (1950) |
| container_volume | 146 |
| creator | Ho, RJ Chong, KT Merigan, TC |
| description | The antiviral activity of recombinant human macrophage CSF (M-CSF) against genital herpes simplex virus type-2 (HSV-2) infection in guinea pigs was investigated. M-CSF stimulates proliferation of human and guinea pig peripheral blood monocytes, specifically the plastic adherent esterase-positive mononuclear cells. When anti-HSV-2 activity of M-CSF was evaluated in guinea pigs by 6 daily injection (s.c.) of M-CSF at various doses (5 x 10(5) to 7 x 10(7) U/kg), we found 2 x 10(6) U/kg to be the optimum dose for protective efficacy against primary HSV-2 infection. Either at a lethal, 5 x 10(5) pfu, or sublethal 5 x 10(4) pfu of virus challenge, animals treated with the optimum regimen of M-CSF exhibited lower herpetic lesion scores (p less than 0.005), and lower mortality (p less than 0.025) than animals in placebo group. M-CSF treatment increased the HSV-infected cell killing activities of plastic-adherent mononuclear cells, indicating that in vivo administration of M-CSF may activate the antiviral effects of guinea pig macrophages that may play a role in protection against severity and mortality of herpetic disease. |
| doi_str_mv | 10.4049/jimmunol.146.10.3578 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_80545819</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>80545819</sourcerecordid><originalsourceid>FETCH-LOGICAL-c441t-bc4aefca92f43363cfb002f57b152183e716b3e9de8889b281aeaca4c898994f3</originalsourceid><addsrcrecordid>eNqFkU2P1DAMhiMEWoaFfwBSDghx6ZC0aSc5rlZ8SStxgXPlZpxOVvkoScvsnPnjpJrh48bJlv34teyXkJecbQUT6t299X4J0W256Lal2LQ7-YhseNuyqutY95hsGKvriu-63VPyLOd7xljHanFFrrhsOVfthvy8CbP9YRM4CnrN5hOFsKf7mJHGabZ-8TQamlBHP9gAYaYedIrTAUakOroYThXNK-hgtmGkpgjFRGOgB0wTZpqtnxw-0BGDncHZTG2g42IDAp3smJ-TJwZcxheXeE2-fXj_9fZTdffl4-fbm7tKC8HnatAC0GhQtRFN0zXaDOU-0-4G3tZcNrjj3dCg2qOUUg215ICgQWippFLCNNfkzVl3SvH7gnnuvc0anYOAccm9ZK1oJVf_BXlXHlm4AoozWB6Sc0LTT8l6SKees341qf9tUl9MWourSWXs1UV_GTzu_w6dXSn915c-ZA3OJAja5j-YUEIIuW5_e8YOdjwcbcI-e3CuiPL-eDz-u_EXcN-tmA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>16006193</pqid></control><display><type>article</type><title>Antiviral activity and dose optimum of recombinant macrophage colony- stimulating factor on herpes simplex genitalis in guinea pigs</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Ho, RJ ; Chong, KT ; Merigan, TC</creator><creatorcontrib>Ho, RJ ; Chong, KT ; Merigan, TC</creatorcontrib><description>The antiviral activity of recombinant human macrophage CSF (M-CSF) against genital herpes simplex virus type-2 (HSV-2) infection in guinea pigs was investigated. M-CSF stimulates proliferation of human and guinea pig peripheral blood monocytes, specifically the plastic adherent esterase-positive mononuclear cells. When anti-HSV-2 activity of M-CSF was evaluated in guinea pigs by 6 daily injection (s.c.) of M-CSF at various doses (5 x 10(5) to 7 x 10(7) U/kg), we found 2 x 10(6) U/kg to be the optimum dose for protective efficacy against primary HSV-2 infection. Either at a lethal, 5 x 10(5) pfu, or sublethal 5 x 10(4) pfu of virus challenge, animals treated with the optimum regimen of M-CSF exhibited lower herpetic lesion scores (p less than 0.005), and lower mortality (p less than 0.025) than animals in placebo group. M-CSF treatment increased the HSV-infected cell killing activities of plastic-adherent mononuclear cells, indicating that in vivo administration of M-CSF may activate the antiviral effects of guinea pig macrophages that may play a role in protection against severity and mortality of herpetic disease.</description><identifier>ISSN: 0022-1767</identifier><identifier>EISSN: 1550-6606</identifier><identifier>DOI: 10.4049/jimmunol.146.10.3578</identifier><identifier>PMID: 1851195</identifier><identifier>CODEN: JOIMA3</identifier><language>eng</language><publisher>Bethesda, MD: Am Assoc Immnol</publisher><subject>Animals ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiviral agents ; Antiviral Agents - pharmacology ; Biological and medical sciences ; Cytotoxicity, Immunologic ; Female ; Guinea Pigs ; Herpes Genitalis - immunology ; Herpes Genitalis - prevention & control ; Macrophage Colony-Stimulating Factor - administration & dosage ; Macrophage Colony-Stimulating Factor - pharmacology ; Macrophages - physiology ; Medical sciences ; Monocytes - drug effects ; Pharmacology. Drug treatments ; Recombinant Proteins - administration & dosage ; Recombinant Proteins - pharmacology ; Simplexvirus - drug effects</subject><ispartof>The Journal of immunology (1950), 1991-05, Vol.146 (10), p.3578-3582</ispartof><rights>1992 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c441t-bc4aefca92f43363cfb002f57b152183e716b3e9de8889b281aeaca4c898994f3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=4944483$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1851195$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ho, RJ</creatorcontrib><creatorcontrib>Chong, KT</creatorcontrib><creatorcontrib>Merigan, TC</creatorcontrib><title>Antiviral activity and dose optimum of recombinant macrophage colony- stimulating factor on herpes simplex genitalis in guinea pigs</title><title>The Journal of immunology (1950)</title><addtitle>J Immunol</addtitle><description>The antiviral activity of recombinant human macrophage CSF (M-CSF) against genital herpes simplex virus type-2 (HSV-2) infection in guinea pigs was investigated. M-CSF stimulates proliferation of human and guinea pig peripheral blood monocytes, specifically the plastic adherent esterase-positive mononuclear cells. When anti-HSV-2 activity of M-CSF was evaluated in guinea pigs by 6 daily injection (s.c.) of M-CSF at various doses (5 x 10(5) to 7 x 10(7) U/kg), we found 2 x 10(6) U/kg to be the optimum dose for protective efficacy against primary HSV-2 infection. Either at a lethal, 5 x 10(5) pfu, or sublethal 5 x 10(4) pfu of virus challenge, animals treated with the optimum regimen of M-CSF exhibited lower herpetic lesion scores (p less than 0.005), and lower mortality (p less than 0.025) than animals in placebo group. M-CSF treatment increased the HSV-infected cell killing activities of plastic-adherent mononuclear cells, indicating that in vivo administration of M-CSF may activate the antiviral effects of guinea pig macrophages that may play a role in protection against severity and mortality of herpetic disease.</description><subject>Animals</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiviral agents</subject><subject>Antiviral Agents - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Cytotoxicity, Immunologic</subject><subject>Female</subject><subject>Guinea Pigs</subject><subject>Herpes Genitalis - immunology</subject><subject>Herpes Genitalis - prevention & control</subject><subject>Macrophage Colony-Stimulating Factor - administration & dosage</subject><subject>Macrophage Colony-Stimulating Factor - pharmacology</subject><subject>Macrophages - physiology</subject><subject>Medical sciences</subject><subject>Monocytes - drug effects</subject><subject>Pharmacology. Drug treatments</subject><subject>Recombinant Proteins - administration & dosage</subject><subject>Recombinant Proteins - pharmacology</subject><subject>Simplexvirus - drug effects</subject><issn>0022-1767</issn><issn>1550-6606</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1991</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU2P1DAMhiMEWoaFfwBSDghx6ZC0aSc5rlZ8SStxgXPlZpxOVvkoScvsnPnjpJrh48bJlv34teyXkJecbQUT6t299X4J0W256Lal2LQ7-YhseNuyqutY95hsGKvriu-63VPyLOd7xljHanFFrrhsOVfthvy8CbP9YRM4CnrN5hOFsKf7mJHGabZ-8TQamlBHP9gAYaYedIrTAUakOroYThXNK-hgtmGkpgjFRGOgB0wTZpqtnxw-0BGDncHZTG2g42IDAp3smJ-TJwZcxheXeE2-fXj_9fZTdffl4-fbm7tKC8HnatAC0GhQtRFN0zXaDOU-0-4G3tZcNrjj3dCg2qOUUg215ICgQWippFLCNNfkzVl3SvH7gnnuvc0anYOAccm9ZK1oJVf_BXlXHlm4AoozWB6Sc0LTT8l6SKees341qf9tUl9MWourSWXs1UV_GTzu_w6dXSn915c-ZA3OJAja5j-YUEIIuW5_e8YOdjwcbcI-e3CuiPL-eDz-u_EXcN-tmA</recordid><startdate>19910515</startdate><enddate>19910515</enddate><creator>Ho, RJ</creator><creator>Chong, KT</creator><creator>Merigan, TC</creator><general>Am Assoc Immnol</general><general>American Association of Immunologists</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>19910515</creationdate><title>Antiviral activity and dose optimum of recombinant macrophage colony- stimulating factor on herpes simplex genitalis in guinea pigs</title><author>Ho, RJ ; Chong, KT ; Merigan, TC</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c441t-bc4aefca92f43363cfb002f57b152183e716b3e9de8889b281aeaca4c898994f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1991</creationdate><topic>Animals</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiviral agents</topic><topic>Antiviral Agents - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Cytotoxicity, Immunologic</topic><topic>Female</topic><topic>Guinea Pigs</topic><topic>Herpes Genitalis - immunology</topic><topic>Herpes Genitalis - prevention & control</topic><topic>Macrophage Colony-Stimulating Factor - administration & dosage</topic><topic>Macrophage Colony-Stimulating Factor - pharmacology</topic><topic>Macrophages - physiology</topic><topic>Medical sciences</topic><topic>Monocytes - drug effects</topic><topic>Pharmacology. Drug treatments</topic><topic>Recombinant Proteins - administration & dosage</topic><topic>Recombinant Proteins - pharmacology</topic><topic>Simplexvirus - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ho, RJ</creatorcontrib><creatorcontrib>Chong, KT</creatorcontrib><creatorcontrib>Merigan, TC</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of immunology (1950)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ho, RJ</au><au>Chong, KT</au><au>Merigan, TC</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antiviral activity and dose optimum of recombinant macrophage colony- stimulating factor on herpes simplex genitalis in guinea pigs</atitle><jtitle>The Journal of immunology (1950)</jtitle><addtitle>J Immunol</addtitle><date>1991-05-15</date><risdate>1991</risdate><volume>146</volume><issue>10</issue><spage>3578</spage><epage>3582</epage><pages>3578-3582</pages><issn>0022-1767</issn><eissn>1550-6606</eissn><coden>JOIMA3</coden><abstract>The antiviral activity of recombinant human macrophage CSF (M-CSF) against genital herpes simplex virus type-2 (HSV-2) infection in guinea pigs was investigated. M-CSF stimulates proliferation of human and guinea pig peripheral blood monocytes, specifically the plastic adherent esterase-positive mononuclear cells. When anti-HSV-2 activity of M-CSF was evaluated in guinea pigs by 6 daily injection (s.c.) of M-CSF at various doses (5 x 10(5) to 7 x 10(7) U/kg), we found 2 x 10(6) U/kg to be the optimum dose for protective efficacy against primary HSV-2 infection. Either at a lethal, 5 x 10(5) pfu, or sublethal 5 x 10(4) pfu of virus challenge, animals treated with the optimum regimen of M-CSF exhibited lower herpetic lesion scores (p less than 0.005), and lower mortality (p less than 0.025) than animals in placebo group. M-CSF treatment increased the HSV-infected cell killing activities of plastic-adherent mononuclear cells, indicating that in vivo administration of M-CSF may activate the antiviral effects of guinea pig macrophages that may play a role in protection against severity and mortality of herpetic disease.</abstract><cop>Bethesda, MD</cop><pub>Am Assoc Immnol</pub><pmid>1851195</pmid><doi>10.4049/jimmunol.146.10.3578</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-1767 |
| ispartof | The Journal of immunology (1950), 1991-05, Vol.146 (10), p.3578-3582 |
| issn | 0022-1767 1550-6606 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_80545819 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Animals Antibiotics. Antiinfectious agents. Antiparasitic agents Antiviral agents Antiviral Agents - pharmacology Biological and medical sciences Cytotoxicity, Immunologic Female Guinea Pigs Herpes Genitalis - immunology Herpes Genitalis - prevention & control Macrophage Colony-Stimulating Factor - administration & dosage Macrophage Colony-Stimulating Factor - pharmacology Macrophages - physiology Medical sciences Monocytes - drug effects Pharmacology. Drug treatments Recombinant Proteins - administration & dosage Recombinant Proteins - pharmacology Simplexvirus - drug effects |
| title | Antiviral activity and dose optimum of recombinant macrophage colony- stimulating factor on herpes simplex genitalis in guinea pigs |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T02%3A19%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antiviral%20activity%20and%20dose%20optimum%20of%20recombinant%20macrophage%20colony-%20stimulating%20factor%20on%20herpes%20simplex%20genitalis%20in%20guinea%20pigs&rft.jtitle=The%20Journal%20of%20immunology%20(1950)&rft.au=Ho,%20RJ&rft.date=1991-05-15&rft.volume=146&rft.issue=10&rft.spage=3578&rft.epage=3582&rft.pages=3578-3582&rft.issn=0022-1767&rft.eissn=1550-6606&rft.coden=JOIMA3&rft_id=info:doi/10.4049/jimmunol.146.10.3578&rft_dat=%3Cproquest_cross%3E80545819%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=16006193&rft_id=info:pmid/1851195&rfr_iscdi=true |